Home>>MCP110

MCP110

Catalog No.GC61032

MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.

Products are for research use only. Not for human use. We do not sell to patients.

MCP110 Chemical Structure

Cas No.: 521310-51-0

Size Price Stock Qty
5mg
$185.00
In stock
10mg
$324.00
In stock
50mg
$881.00
In stock
100mg
$1,251.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors[1].

MCP110 (10 and 20 uM) inhibits H-Ras (V12)-induced AP-1 activation in HEK293 cells. Ras stimulation of Raf-1 activity is significantly decreased by MCP110 (20 μM) [1].MCP110 (1, 2, 5, 10, and 20 μM) shows a dose-dependent inhibition of elevated Raf-1 activity in fibrosarcoma HT1080 cells[1].MCP110 (20 μM) decreases cyclin D level stimulated by the treatment with EGF (100 ng/mL), platelet-derived growth factor (20 ng/mL) , serum, or phorbol 12-myristate 13-acetate (100 nM) in A549 cells[1].

[1]. Juran Kato-Stankiewicz,et al. Inhibitors of Ras/Raf-1 Interaction Identified by Two-Hybrid Screening Revert Ras-dependent Transformation Phenotypes in Human Cancer Cells. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403.

Reviews

Review for MCP110

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MCP110

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.